Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis

Next Previous
Trial Profile

A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Seborrhoeic dermatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Arcutis Biotherapeutics

Most Recent Events

  • 08 Jan 2024 According to an Arcutis Biotherapeutics media release, based on results from STRATUM and the Phase 2 Trial 203, the Health Canada has accepted for review the Supplement to a New Drug Submission (SNDS) for roflumilast foam 0.3%, a steroid-free, once-daily phosphodiesterase-4 (PDE4) inhibitor for the topical treatment of seborrheic dermatitis in adult and adolescent patients 9 years of age and older.
  • 15 Dec 2023 According to an Arcutis Biotherapeutics media release, based on results from STRATUM and the Phase 2 Trial 203, the U.S. Food and Drug Administration (FDA) has approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older.
  • 03 May 2023 Results assessing safety and efficacy of roflumilast foam in seborrheic dermatitis patients were published in the JAMA Dermatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top